Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Eli Lilly and Company enters the final three weeks before its Q3 print with the analyst upgrade cycle accelerating, short interest still negligible, and the stock trading roughly 13% below a consensus target that keeps drifting higher.
The freshest development is on the Street. Morgan Stanley's Terence Flynn raised his price target this morning to $1,430, up from $1,419, maintaining Overweight. That follows JP Morgan's Chris Schott lifting to $1,500 on September 28, which remains the most aggressive call from a major bank. The consensus mean now stands at $1,329, about 15% above the current price of $1,157. The direction of travel among analysts is almost uniformly upward: multiple firms have raised targets over the past month, and the only meaningful holdout is HSBC, which carries a Reduce rating with a $940 target. The bull case centres on tirzepatide momentum in Mounjaro and Zepbound, a raised long-term EPS CAGR target of 18% through 2032, and the recently approved Inluriyo label update. Bears flag slowing ramp assumptions for Foundayo, rising competitive threats to Emgality and Verzenio, and pipeline execution risk on orforglipron and retatrutide. The analyst consensus ranks in the 92nd percentile for recommendation strength across the ORTEX universe, though the forward EPS year-on-year score of 33 reflects caution about the near-term earnings trajectory.
Short interest is not a meaningful angle here. At 0.85% of the free float, the short position is minimal and has been range-bound. It ticked up roughly 5% on the week in share terms but remains near its lowest levels of the past six weeks. Borrow conditions back that up: the cost to borrow has eased 7% on the week to 0.34%, and availability is effectively uncapped, with over 664 million shares available to lend against a short position of roughly 7.6 million. There is no squeeze pressure, and no structural short thesis worth flagging. Options positioning is equally unremarkable. The put/call ratio of 1.17 is almost exactly in line with its 20-day average of 1.17, with a z-score near zero. The 52-week range runs from 0.76 to 1.37, so the current reading sits in the middle of a wide band, neither defensively positioned nor particularly bullish. Taken together, the positioning picture is calm rather than charged.
Valuation multiples have drifted modestly higher over the past month. The trailing PE has expanded about half a point to 25.7, and EV/EBITDA is near 20.7. Those are not cheap multiples, but the EPS momentum scores of 79 and 78 over 30 and 90 days respectively suggest the earnings revision cycle is still working in the stock's favour. The stock is down 2.3% on the week, roughly in line with peers: JNJ fell 4.8%, MRK dropped 4.9%, and AZN gave back 3.8%, so Lilly's modest underperformance relative to the previous note's context looks more like a sector rotation than a company-specific move.
On the insider register, the recent activity is not a signal worth overweighting. Four directors received small stock grants totalling under $45,000 combined on September 21, which are compensation mechanics rather than conviction buys. The one notable trade in the 90-day window was EVP Patrik Jonsson's sale of 6,500 shares in August at $1,175 for roughly $7.6 million, filed under a pre-arranged 10b5-1 plan. Planned sales of that kind carry far less information content than discretionary open-market transactions. Net insider activity over 90 days comes to a negative 13,500 shares, but the 10b5-1 designation removes most of the signal. The Lilly Endowment remains the anchor holder at roughly 10.1% of shares, with BlackRock and Vanguard entities collectively holding another 14%. No Schedule 13D activist is on the register.
The earnings reaction history offers a reference point worth noting. The two most recent prints produced a 6.8% one-day gain and a 2.7% one-day gain respectively, with the August 2026 result extending to a 9.4% five-day move. With Q3 results due October 29 and 22 days to go, how the Street interprets the Foundayo ramp trajectory and any update on the oral GLP-1 pipeline will matter as much as the headline numbers themselves.
See the live data behind this article on ORTEX.
Open LLY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
